BACKGROUND: Recent artemisinin-combination therapy failures in Cambodia prompted a search for alternatives. Atovaquone-proguanil (AP), a safe, effective treatment for multidrug-resistant Plasmodium falciparum (P.f.), previously demonstrated additive effects in combination with artesunate (AS). METHODS: Patients with P.f. or mixed-species infection (n = 205) in Anlong Veng (AV; n = 157) and Kratie (KT; n = 48), Cambodia, were randomized open-label 1:1 to a fixed-dose 3-day AP regimen +/-3 days of co-administered artesunate (ASAP). Single low-dose primaquine (PQ, 15 mg) was given on day 1 to prevent gametocyte-mediated transmission. RESULTS: Polymerase chain reaction-adjusted adequate clinical and parasitological response at 42 days was 90% for AP (95% confidence interval [CI], 82%-95%) and 92% for ASAP (95% CI, 83%-96%; P = .73). The median parasite clearance time was 72 hours for ASAP in AV vs 56 hours in KT (P < .001) and was no different than AP alone. At 1 week postprimaquine, 7% of the ASAP group carried microscopic gametocytes vs 29% for AP alone (P = .0001). Nearly all P.f. isolates had C580Y K13 propeller artemisinin resistance mutations (AV 99%; KT 88%). Only 1 of 14 treatment failures carried the cytochrome bc1 (Pfcytb) atovaquone resistance mutation, which was not present at baseline. P.f. isolates remained atovaquone sensitive in vitro but cycloguanil resistant, with a triple P.f. dihydrofolate reductase mutation. CONCLUSIONS: Atovaquone-proguanil remained marginally effective in Cambodia (≥90%) with minimal Pfcytb mutations observed. Treatment failures in the presence of ex vivo atovaquone sensitivity and adequate plasma levels may be attributable to cycloguanil and/or artemisinin resistance. Artesunate co-administration provided little additional blood-stage efficacy but reduced post-treatment gametocyte carriage in combination with AP beyond single low-dose primaquine. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2019.
BACKGROUND: Recent artemisinin-combination therapy failures in Cambodia prompted a search for alternatives. Atovaquone-proguanil (AP), a safe, effective treatment for multidrug-resistant Plasmodium falciparum (P.f.), previously demonstrated additive effects in combination with artesunate (AS). METHODS: Patients with P.f. or mixed-species infection (n = 205) in Anlong Veng (AV; n = 157) and Kratie (KT; n = 48), Cambodia, were randomized open-label 1:1 to a fixed-dose 3-day AP regimen +/-3 days of co-administered artesunate (ASAP). Single low-dose primaquine (PQ, 15 mg) was given on day 1 to prevent gametocyte-mediated transmission. RESULTS: Polymerase chain reaction-adjusted adequate clinical and parasitological response at 42 days was 90% for AP (95% confidence interval [CI], 82%-95%) and 92% for ASAP (95% CI, 83%-96%; P = .73). The median parasite clearance time was 72 hours for ASAP in AV vs 56 hours in KT (P < .001) and was no different than AP alone. At 1 week postprimaquine, 7% of the ASAP group carried microscopic gametocytes vs 29% for AP alone (P = .0001). Nearly all P.f. isolates had C580Y K13 propeller artemisinin resistance mutations (AV 99%; KT 88%). Only 1 of 14 treatment failures carried the cytochrome bc1 (Pfcytb) atovaquone resistance mutation, which was not present at baseline. P.f. isolates remained atovaquone sensitive in vitro but cycloguanil resistant, with a triple P.f. dihydrofolate reductase mutation. CONCLUSIONS: Atovaquone-proguanil remained marginally effective in Cambodia (≥90%) with minimal Pfcytb mutations observed. Treatment failures in the presence of ex vivo atovaquone sensitivity and adequate plasma levels may be attributable to cycloguanil and/or artemisinin resistance. Artesunate co-administration provided little additional blood-stage efficacy but reduced post-treatment gametocyte carriage in combination with AP beyond single low-dose primaquine. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2019.
Entities:
Keywords:
artesunate; atovaquone-proguanil; drug resistance; malaria; primaquine
Authors: Olivo Miotto; Roberto Amato; Elizabeth A Ashley; Bronwyn MacInnis; Jacob Almagro-Garcia; Chanaki Amaratunga; Pharath Lim; Daniel Mead; Samuel O Oyola; Mehul Dhorda; Mallika Imwong; Charles Woodrow; Magnus Manske; Jim Stalker; Eleanor Drury; Susana Campino; Lucas Amenga-Etego; Thuy-Nhien Nguyen Thanh; Hien Tinh Tran; Pascal Ringwald; Delia Bethell; Francois Nosten; Aung Pyae Phyo; Sasithon Pukrittayakamee; Kesinee Chotivanich; Char Meng Chuor; Chea Nguon; Seila Suon; Sokunthea Sreng; Paul N Newton; Mayfong Mayxay; Maniphone Khanthavong; Bouasy Hongvanthong; Ye Htut; Kay Thwe Han; Myat Phone Kyaw; Md Abul Faiz; Caterina I Fanello; Marie Onyamboko; Olugbenga A Mokuolu; Christopher G Jacob; Shannon Takala-Harrison; Christopher V Plowe; Nicholas P Day; Arjen M Dondorp; Chris C A Spencer; Gilean McVean; Rick M Fairhurst; Nicholas J White; Dominic P Kwiatkowski Journal: Nat Genet Date: 2015-01-19 Impact factor: 38.330
Authors: Panita Gosi; Charlotte A Lanteri; Stuart D Tyner; Youry Se; Chanthap Lon; Michele Spring; Mengchuor Char; Darapiseth Sea; Sabaithip Sriwichai; Sittidech Surasri; Saowaluk Wongarunkochakorn; Kingkan Pidtana; Douglas S Walsh; Mark M Fukuda; Jessica Manning; David L Saunders; Delia Bethell Journal: Malar J Date: 2013-11-09 Impact factor: 2.979
Authors: Jessica T Lin; Chanthap Lon; Michele D Spring; Somethy Sok; Soklyda Chann; Mali Ittiverakul; Worachet Kuntawunginn; Mok My; Kheangheng Thay; Rifat Rahman; Sujata Balasubramanian; Mengchuor Char; Charlotte A Lanteri; Panita Gosi; Ratawan Ubalee; Steven R Meshnick; David L Saunders Journal: PLoS One Date: 2017-06-07 Impact factor: 3.240
Authors: Ole Wichmann; Marion Muehlen; Holger Gruss; Frank P Mockenhaupt; Norbert Suttorp; Tomas Jelinek Journal: Malar J Date: 2004-06-08 Impact factor: 2.979
Authors: Christian M Parobek; Jonathan B Parr; Nicholas F Brazeau; Chanthap Lon; Suwanna Chaorattanakawee; Panita Gosi; Eric J Barnett; Lauren D Norris; Steven R Meshnick; Michele D Spring; Charlotte A Lanteri; Jeffrey A Bailey; David L Saunders; Jessica T Lin; Jonathan J Juliano Journal: Genome Biol Evol Date: 2017-06-01 Impact factor: 3.416
Authors: Jessica T Lin; Andreea Waltmann; Kara A Moser; Zackary Park; Yu Bin Na; Ozkan Aydemir; Nicholas F Brazeau; Panita Gosi; Patrick W Marsh; Meredith S Muller; Michele Spring; Somethy Sok; Jeffrey A Bailey; David L Saunders; Chanthap Lon; Mariusz Wojnarski Journal: Antimicrob Agents Chemother Date: 2021-02-17 Impact factor: 5.191
Authors: Biraj Shrestha; Zalak Shah; Andrew P Morgan; Piyaporn Saingam; Chaiyaporn Chaisatit; Suwanna Chaorattanakawee; Chantida Praditpol; Nonlawat Boonyalai; Paphavee Lertsethtakarn; Mariusz Wojnarski; Molly Deutsch-Feldman; Matthew Adams; Darapiseth Sea; Soklyda Chann; Stuart D Tyner; Charlotte A Lanteri; Michele D Spring; David L Saunders; Philip L Smith; Chanthap Lon; Panita Gosi; Somethy Sok; Prom Satharath; Huy Rekol; Dysoley Lek; Brian A Vesely; Jessica T Lin; Norman C Waters; Shannon Takala-Harrison Journal: J Infect Dis Date: 2021-09-17 Impact factor: 5.226
Authors: Nonlawat Boonyalai; Brian A Vesely; Chatchadaporn Thamnurak; Chantida Praditpol; Watcharintorn Fagnark; Kirakarn Kirativanich; Piyaporn Saingam; Chaiyaporn Chaisatit; Paphavee Lertsethtakarn; Panita Gosi; Worachet Kuntawunginn; Pattaraporn Vanachayangkul; Michele D Spring; Mark M Fukuda; Chanthap Lon; Philip L Smith; Norman C Waters; David L Saunders; Mariusz Wojnarski Journal: Malar J Date: 2020-07-25 Impact factor: 2.979
Authors: Nonlawat Boonyalai; Kirakarn Kirativanich; Chatchadaporn Thamnurak; Chantida Praditpol; Brian A Vesely; Mariusz Wojnarski; John S Griesenbeck; Norman C Waters Journal: Malar J Date: 2022-04-22 Impact factor: 3.469
Authors: Donelly A van Schalkwyk; Michael K Riscoe; Sovitj Pou; Rolf W Winter; Aaron Nilsen; Maëlle Duffey; Robert W Moon; Colin J Sutherland Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.938